NIH #1R43CA102804-01
Development of antagonists for oncogenic K+ channel KCNB
- Amount
- $250K
- Period
- 2003-08-11 → 2004-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at TULARIK, INC.
Cancer Cells and Metastasis · Oncology
1 total · 0 active
NIH #1R43CA102804-01
Awarded at TULARIK, INC.
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
BPS2026 – Exclusive protein interactions are responsible for functional competition
Biophysical Journal · 2026-02-01
Maintenance of Energy Metabolism Is an Integral Part of Plakophilin-2 and Desmosome Functions
JACC Basic to Translational Science · 2025-12-01 · 1 citations
JACC Basic to Translational Science · 2025-10-18
bioRxiv (Cold Spring Harbor Laboratory) · 2025-08-04
Heart Rhythm · 2025-04-01
Nature Communications · 2025-03-04 · 34 citations
bioRxiv (Cold Spring Harbor Laboratory) · 2025-01-20 · 1 citations
Author Correction: Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice
Nature Communications · 2024-10-09 · 3 citations
Circulation Research · 2024-08-02